期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 17, 期 6, 页码 1486-1496出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.59149
关键词
therapeutic antibody; COVID-19; SARS-CoV-2; convalescent plasma; antibody cocktail; monoclonal antibody
资金
- National Natural Science Foundation of China [62071099]
The global health crisis caused by the COVID-19 pandemic continues, with many therapeutic antibody treatments in development and authorized for emergency use by the FDA. Ongoing clinical trials worldwide have shown therapeutic antibody therapies to be a crucial part of COVID-19 treatment.
The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis. Fundamental studies at genome, transcriptome, proteome, and interactome levels have revealed many viral and host targets for therapeutic interventions. Hundreds of antibodies for treating COVID-19 have been developed at preclinical and clinical stages in the format of polyclonal antibodies, monoclonal antibodies, and cocktail antibodies. Four products, i.e., convalescent plasma, bamlanivimab, REGN-Cov2, and the cocktail of bamlanivimab and etesevimab have been authorized by the U.S. Food and Drug Administration (FDA) for emergency use. Hundreds of relevant clinical trials are ongoing worldwide. Therapeutic antibody therapies have been a very active and crucial part of COVID-19 treatment. In this review, we focus on the progress of therapeutic COVID-19 antibody development and application, discuss corresponding problems and challenges, suggesting new strategies and solutions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据